PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400997
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400997
Human Chorionic Gonadotropin (hCG) Market size was valued at USD 710.87 Million in 2022, expanding at a CAGR of 6.48% from 2023 to 2030.
Human Chorionic Gonadotropin (hCG) is a hormone generated by the placenta during pregnancy. It aids pregnancy by activating the corpus luteum in the ovaries to generate progesterone, which maintains the uterine lining and helps the growing fetus. hCG is also the hormone discovered in pregnancy tests since its levels grow considerably early in pregnancy. In addition to its role in reproduction, hCG has therapeutic applications, including as in fertility therapies and as a marker for various medical disorders, including several cancer technologies.
Human Chorionic Gonadotropin (hCG) Market- Market Dynamics
Increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment to propel market demand
The rising prevalence of infertility and hypogonadism, changing lifestyles, and improved knowledge about infertility therapy are all contributing to the expansion of the human chorionic gonadotropin (HCG) industry. Hypogonadism, for example, is defined by low serum the hormone testosterone concentration, which is followed by an array of clinical features such as poor morning erections, ED, memory loss, low libido, physical decline in health and power, difficulty concentrating, and depression. According to research published in July 2021 by BMC Endocrine Disorders, erectile dysfunction would affect 72.2% of adults worldwide in 2021.
Human Chorionic Gonadotropin (hCG) Market- Key Insights
As per the analysis shared by our research analyst, the global Human Chorionic Gonadotropin (hCG) market is estimated to grow annually at a CAGR of around 6.48% over the forecast period (2023-2030)
The Human Chorionic Gonadotropin (hCG) industry is projected to grow at a significant rate due to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment
Based on Technology segmentation, natural source extraction was predicted to show maximum market share in the year 2022
Based on Therapeutic Area segmentation, Female Infertility Treatment was the leading Technology in 2022
Based on end user segmentation, Fertility Clinics was the leading Technology in 2022
On the basis of region, North America was the leading revenue generator in 2022
The Global Human Chorionic Gonadotropin (hCG) Market is segmented on the basis of Technology, Therapeutic Area, End User, and Region.
The market is divided into categories based on product Technology: Recombinant Technology and Natural Source Extraction. The natural source extraction segment dominated the worldwide market and is likely to continue to do so during the forecast period. The leading competitors in the hCG sector have a high demand for gonadotropins derived from natural sources, which has been an important development in the market over the past few years and has contributed significantly to the income earned by this segment.
The market is divided into categories based on Therapeutic Area: Male Hypogonadism, Female Infertility Treatment, Oligospermia Treatment, and Others. Infertility is described as the couple's inability to become pregnant or the woman's inability to sustain a pregnancy to term. Because the human chorionic gonadotropin (HCG) hormone is important following embryo development during pregnancy, its usage in infertility therapy has gained popularity in both men and women. Female infertility can be caused by a variety of factors. Tubal abnormalities such as a uterine illness, blocked fallopian tube, follicular problems, polycystic ovarian syndrome (PCOS), various and endocrine system disorders are among the leading causes, according to the World Health Organization.
Human Chorionic Gonadotropin (hCG) Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Over the projection period, North America is expected to experience considerable market growth. The rise can be linked to the region's well-established healthcare infrastructure, advantageous reimbursement regulations, and the rising burden of infertility.
Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, in June 2022, Inception Fertility extended its ecosystem with the introduction of HavenCryo, a long-term biological tissue and cryopreservation preservation solution that provides fertility professionals and patients with a one-of-a-kind experience.
In June 2022, with the introduction of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that provides a distinctive experience for fertility practitioners and patients, Inception Fertility extended its ecosystem.
The scope of this report covers the market by its major segments, which include as follows: